CYT 1010
Alternative Names: CYT 1010; Cyt1010Latest Information Update: 05 Mar 2021
Price :
$50 *
At a glance
- Originator Tulane University
- Developer Cytogel
- Class Analgesics; Peptides
- Mechanism of Action Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Pain
Highest Development Phases
- Phase II Acute pain
- Preclinical Pain
Most Recent Events
- 05 Mar 2021 Phase-II clinical trials in Acute pain in USA (IV), prior to March 2021 (Cytogel Pharma pipeline, March 2021)
- 05 Mar 2021 Preclinical trials in Acute pain in USA (PO), prior to March 2021 (Cytogel Pharma pipeline, March 2021)
- 05 Mar 2021 Preclinical trials in Pain in USA (PO), prior to March 2021 (Cytogel Pharma pipeline, March 2021)